JP2022523355A - 神経障害の処置のための重水素化キサノメリンの化合物及び方法 - Google Patents

神経障害の処置のための重水素化キサノメリンの化合物及び方法 Download PDF

Info

Publication number
JP2022523355A
JP2022523355A JP2021549216A JP2021549216A JP2022523355A JP 2022523355 A JP2022523355 A JP 2022523355A JP 2021549216 A JP2021549216 A JP 2021549216A JP 2021549216 A JP2021549216 A JP 2021549216A JP 2022523355 A JP2022523355 A JP 2022523355A
Authority
JP
Japan
Prior art keywords
compound
agent
milligrams
formula
trospium chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523355A5 (https=
Inventor
ベネット デニス
アッタード ジョージオ
シュレヒト クリフォード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karuna Therapeutics Inc
Original Assignee
Karuna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karuna Therapeutics Inc filed Critical Karuna Therapeutics Inc
Publication of JP2022523355A publication Critical patent/JP2022523355A/ja
Publication of JP2022523355A5 publication Critical patent/JP2022523355A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021549216A 2019-02-22 2020-02-21 神経障害の処置のための重水素化キサノメリンの化合物及び方法 Pending JP2022523355A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962808954P 2019-02-22 2019-02-22
US62/808,954 2019-02-22
US201962936358P 2019-11-15 2019-11-15
US62/936,358 2019-11-15
PCT/US2020/019193 WO2020172516A1 (en) 2019-02-22 2020-02-21 Compounds and methods of deuterated xanomeline for treating neurological disorders

Publications (2)

Publication Number Publication Date
JP2022523355A true JP2022523355A (ja) 2022-04-22
JP2022523355A5 JP2022523355A5 (https=) 2023-03-09

Family

ID=72145029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549216A Pending JP2022523355A (ja) 2019-02-22 2020-02-21 神経障害の処置のための重水素化キサノメリンの化合物及び方法

Country Status (8)

Country Link
US (1) US20220144817A1 (https=)
EP (1) EP3927342A4 (https=)
JP (1) JP2022523355A (https=)
CN (1) CN113507928A (https=)
AU (1) AU2020226870A1 (https=)
BR (1) BR112021016457A2 (https=)
CA (1) CA3131128A1 (https=)
WO (1) WO2020172516A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
CN115974863B (zh) * 2021-10-14 2024-12-31 南京迈诺威医药科技有限公司 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
US12269818B2 (en) * 2023-04-24 2025-04-08 Terran Biosciences Inc. Analogs of xanomeline
WO2025174424A1 (en) * 2024-02-16 2025-08-21 Terran Biosciences Inc. Analogs of xanomeline, analogs of trospium, and methods of use thereof
CN119161338B (zh) * 2024-11-25 2025-06-17 嘉兴安帝康生物科技有限公司 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508028A (ja) * 1994-10-31 1998-08-04 イーライ・リリー・アンド・カンパニー 不安を治療する方法
JP2012519704A (ja) * 2009-03-05 2012-08-30 ミスリィディオン，インク． 認知増強用化合物及び組成物、製造法、並びに治療法
US20180099956A1 (en) * 2010-09-08 2018-04-12 Neurosolis, Inc. Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2239732A1 (en) * 1995-12-07 1997-06-12 Eli Lilly And Company Method for treating pain
NZ542690A (en) * 2003-03-28 2009-04-30 Acadia Pharm Inc Muscarinic M1 receptor agonists for pain management
US10265311B2 (en) * 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
PT3061821T (pt) * 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508028A (ja) * 1994-10-31 1998-08-04 イーライ・リリー・アンド・カンパニー 不安を治療する方法
JP2012519704A (ja) * 2009-03-05 2012-08-30 ミスリィディオン，インク． 認知増強用化合物及び組成物、製造法、並びに治療法
US20180099956A1 (en) * 2010-09-08 2018-04-12 Neurosolis, Inc. Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, vol. 46, JPN6024004056, 2011, pages 403 - 417, ISSN: 0005406983 *

Also Published As

Publication number Publication date
US20220144817A1 (en) 2022-05-12
CA3131128A1 (en) 2020-08-27
EP3927342A1 (en) 2021-12-29
AU2020226870A1 (en) 2021-09-09
EP3927342A4 (en) 2022-11-16
BR112021016457A2 (pt) 2021-10-13
CN113507928A (zh) 2021-10-15
WO2020172516A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
JP2022523355A (ja) 神経障害の処置のための重水素化キサノメリンの化合物及び方法
EP3423443B1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
US11981681B2 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
US11534434B2 (en) Xanomeline derivatives and methods for treating neurological disorders
EP2311822A1 (en) Gpr119 agonist
JP2009526035A (ja) デュシェンヌ型筋ジストロフィーの治療
JP2023539125A (ja) 有機化合物
EP3724195B1 (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
KR102931436B1 (ko) 유기 화합물
AU2016235534A1 (en) Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
EP3339304A1 (en) Quinoline and isoquinoline derivatives for treating pain and pain related conditions
TW202328111A (zh) 內皮素ａ（ｅｔａ）受體拮抗劑化合物、其藥物組合物及其用途
US9944648B2 (en) Organic compounds
EP4520752A1 (en) Carebastine salt and use thereof
JP2025536577A (ja) イミダゾール化合物とそのナトリウムチャネル阻害剤としての使用
JP4355144B2 (ja) 新規含窒素環状化合物
EP4291552B1 (en) Modulators of complex i
KR20100040881A (ko) 전구약물로서 벤라팍신 및 ｏ－데스메틸벤라팍신의 ｎ－옥사이드
RU2809023C2 (ru) Органические соединения
WO2024059659A1 (en) Cycloalkyl carboxylic acid derivatives as inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
JPH08268949A (ja) ジフェニルメチレン誘導体
MXPA06013484A (es) Metabolitos de (+)-(2s, 3s)-3-(2- metoxi-5- trifluorometoxibencilamino) -2-fenil- piperidina.
HK40039957A (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
HK40039957B (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
HK40041147A (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230301

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240423

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240903